ArticleAnnals of surgical oncology2026
Reappraisal of the Clinical Utility of Hi-Cut Pancreaticoduodenectomy for Widespread Distal Cholangiocarcinoma: A Less Invasive Alternative to Hepatopancreatoduodenectomy.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Combined Model of Inflammatory-Nutritional Indicators and Tumor Markers for Predicting Prognosis in Patients with Distal Cholangiocarcinoma: A Retrospective Cohort Study.Diseases (Basel, Switzerland) · 2026Article
- Development of a prediction model integrating cardiac ultrasound parameters for cardiac complications after distal cholangiocarcinoma surgery: a retrospective cohort study.BMC medical imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe efficacy of Hi-cut pancreaticoduodenectomy (PD) for widespread distal cholangiocarcinoma (DCC) remains unclear. This study re-evaluated the impact of Hi-cut PD on survival, recurrence, and short-term complications.
methodsThe study retrospectively enrolled patients who underwent curative-intent PD for DCC between 2005 and 2021. Hi-cut PD was defined as bile duct resection beyond the midpoint between the superior border of the pancreas and the hepatic duct confluence. Bile duct margin status was classified as group A (negative or carcinoma in situ by PD), group B (negative or carcinoma in situ by Hi-cut PD), or group C (residual invasive cancer by Hi-cut PD).
resultsThe study enrolled 104 patients: 52 (50.0%) in group A, 46 (44.2%) in group B, and 6 (5.8%) in group C. The 5-year overall survival rates in groups A and B were comparable (52.3% vs 52.5%; p = 0.793). The patients without lymph node metastasis had a significantly better 5-year overall survival in group B than in group C (70% vs 25%; p = 0.027). Local recurrence rates were similar between the groups, and major surgical complications (Clavien-Dindo ≥IIIa) were comparable between groups A and B (15.4% vs 21.7%; p = 0.418). Although multiple bile duct orifices were most frequent in group B, the incidence of biliary fistula increased significantly only when five or more orifices were reconstructed (40% vs 4% with one orifice; p = 0.003).
conclusionsHi-cut PD for widespread DCC yielded survival outcomes comparable with PD without increasing local recurrence or major short-term complication rates, supporting its feasibility and oncologic validity as a less invasive alternative to hepatopancreatoduodenectomy for select patients.
Indexed as
Identifiers
41145940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.